UNSPSC 51332834: Acetophenazine dimaleate

This classification denotes an antipsychotic agent with the molecular formula C23H29N3O2S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3P5HNU5JTC, chemically known as ethanone, 1-(10-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl)-10h-phenothiazin-2-yl)-, (z) 2-butenedioate (1:2) (salt), but more generally known as acetophenazine dimaleate, which bears US NIH Compound Identifier 5281082.

European Medicines Agency schedules acetophenazine dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05225MIG. Most nations, for tariff purposes, schedule acetophenazine dimaleate under HS 29343090. SMILES: CC(=O)C1CC2C(CC1)SC3C(CCCC3)N2CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332834 Acetophenazine dimaleate is a Commodity code that nominally describes a single pharmaceutical product, but the recent state and local solicitations tagged under it do not actually involve acetophenazine dimaleate itself. Instead, the code sees activity for broader pharmaceutical procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program implementation. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration). The work involves competitive bidding for pharmaceutical inventories, quarterly deliveries to public health facilities, compliance with FDA and Drug Supply Chain Security Act requirements, and contract administration with fixed or negotiated pricing models.

Recent activity spans Florida, Texas, Minnesota, and Oregon through the MMCAP cooperative. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, due by July 26, 2023 — though this date appears misaligned with the posting date and may reflect a data error in the source. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal award or budget identified at the information-gathering stage. MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026, through three authorized wholesalers and requiring cGMP and DSCSA compliance. The code shows mismatch between its nominal scope (acetophenazine dimaleate, a single drug product) and actual procurement activity (pharmaceutical system procurement and multi-product contracting).